Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

SELL
$2.49 - $20.59 $20,520 - $169,682
-8,241 Reduced 30.25%
19,000 $51,000
Q1 2023

May 12, 2023

SELL
$15.95 - $25.18 $172,802 - $272,800
-10,834 Reduced 28.45%
27,241 $508,000
Q4 2022

Feb 13, 2023

SELL
$13.27 - $17.73 $28,902 - $38,615
-2,178 Reduced 5.41%
38,075 $609,000
Q3 2022

Nov 14, 2022

SELL
$11.4 - $14.6 $14,535 - $18,615
-1,275 Reduced 3.07%
40,253 $524,000
Q2 2022

Aug 11, 2022

BUY
$7.94 - $12.96 $37,087 - $60,536
4,671 Added 12.67%
41,528 $438,000
Q1 2022

May 12, 2022

SELL
$12.02 - $16.79 $96,160 - $134,320
-8,000 Reduced 17.83%
36,857 $443,000
Q4 2021

Feb 11, 2022

SELL
$9.93 - $15.39 $30,783 - $47,709
-3,100 Reduced 6.46%
44,857 $632,000
Q3 2021

Nov 12, 2021

BUY
$10.18 - $26.64 $257,788 - $674,604
25,323 Added 111.88%
47,957 $490,000
Q2 2021

Aug 13, 2021

BUY
$18.57 - $35.68 $178,476 - $342,920
9,611 Added 73.8%
22,634 $602,000
Q1 2021

May 13, 2021

BUY
$31.0 - $55.72 $62 - $111
2 Added 0.02%
13,023 $452,000
Q4 2020

Feb 10, 2021

SELL
$37.09 - $48.97 $211,413 - $279,129
-5,700 Reduced 30.45%
13,021 $482,000
Q3 2020

Nov 12, 2020

SELL
$40.47 - $45.5 $36,423 - $40,950
-900 Reduced 4.59%
18,721 $769,000
Q2 2020

Aug 10, 2020

SELL
$32.57 - $42.83 $32,570 - $42,830
-1,000 Reduced 4.85%
19,621 $795,000
Q1 2020

May 11, 2020

BUY
$23.3 - $45.96 $27,960 - $55,152
1,200 Added 6.18%
20,621 $716,000
Q4 2019

Feb 10, 2020

BUY
$34.58 - $48.06 $266,369 - $370,206
7,703 Added 65.74%
19,421 $832,000
Q3 2019

Nov 13, 2019

BUY
$36.98 - $48.45 $433,331 - $567,737
11,718 New
11,718 $433,000

Others Institutions Holding FGEN

About FIBROGEN INC


  • Ticker FGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,741,200
  • Market Cap $32.8M
  • Description
  • FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...
More about FGEN
Track This Portfolio

Track Martingale Asset Management L P Portfolio

Follow Martingale Asset Management L P and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Martingale Asset Management L P, based on Form 13F filings with the SEC.

News

Stay updated on Martingale Asset Management L P with notifications on news.